Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors

Leukemia Research

Volumn 38, Issue 3, 2014, Pages 294-298

  Efficace, Fabio ^a   Rosti, Gianantonio ^b   Cottone, Francesco ^a   Breccia, Massimo ^c   Castagnetti, Fausto ^b   Iurlo, Alessandra ^d   Mandelli, Franco ^a   Baccarani, Michele ^c  

^a Data Center and Health Outcomes Research Unit   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Adherence to therapy; Chronic myeloid leukemia; Quality of life; Symptoms

Indexed keywords

ADHERENCE TO THERAPY; CHRONIC MYELOID LEUKEMIA; QUALITY OF LIFE; SYMPTOMS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUALITY OF LIFE; SEX FACTORS; TREATMENT OUTCOME;

EID: 84894276295     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.07.003     Document Type: Article

References (18)

1. Noens L., van Lierde M.A., De Bock R., Verhoef G., Zachee P., Berneman Z., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113:5401-5411.
2. Marin D., Bazeos A., Mahon F.X., Eliasson L., Milojkovic D., Bua M., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28:2381-2388.
3. Cramer J.A., Roy A., Burrell A., Fairchild C.J., Fuldeore M.J., Ollendorf D.A., et al. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11:44-47.
4. Efficace F., Baccarani M., Rosti G., Cottone F., Castagnetti F., Breccia M., et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer 2012, 107:904-909.
5. Breccia M., Efficace F., Alimena G. Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Leuk Res 2012, 36:804-805.
6. Gadkari A.S., McHorney C.A. Unintentional non-adherence to chronic prescription medications: how unintentional is it really?. BMC Health Serv Res 2012, 12:98.
7. Eliasson L., Clifford S., Barber N., Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 2011, 35:626-630.
8. Efficace F., Baccarani M., Breccia M., Alimena G., Rosti G., Cottone F., et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011, 118:4554-4560.
9. Efficace F., Cardoni A., Cottone F., Vignetti M., Mandelli F. Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review. Leuk Res 2013, 37:206-213.
10. Efficace F., Baccarani M., Breccia M., Cottone F., Alimena G., Deliliers G.L., et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 2013, 27:1511-1519.
11. Phillips K.M., Pinilla-Ibarz J., Sotomayor E., Lee M.R., Jim H.S., Small B.J., et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer 2013, 21:1097-1103.
12. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24:67-74.
13. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
14. Efficace F., Breccia M., Baccarani M., Alimena G., Lambertenghi Deliliers G., Specchia G., et al. Development and feasibility of a patient-reported symptom checklist for chronic myeloid leukemia patients. Haematologica 2010, 95(S2):189. [abstract 0465].
15. Sloan J., Symonds T., Vargas-Chanes D., Fridley B. Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. Drug Inf J 2003, 37:23-31.
16. Kripalani S., Yao X., Haynes R.B. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007, 167:540-550.
17. Sharf G., Hoffmann V., Bombaci F., Daban M., De Jong J., Gavin T., et al. Non-adherence in Chronic Myeloid Leukemia: Results of a global survey of 2546 CML patients in 79 countries. Haematologica 2013, 98(June (S1)):453. [abstract 104].
18. Ruddy K., Mayer E., Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009, 59:56-66.